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Delayed cerebral ischemia (DCI) is a feared complication 
and an important cause of poor outcome after aneurys-
mal subarachnoid hemorrhage (SAH). Only limited 
progress has been made in the prevention of DCI. More 
than 20  years ago, the calcium antagonist nimodipine 
was identiﬁ  ed as a drug that decreases the risk of DCI. 
However, the eﬀ  ect of nimodipine is only modest. Many 
patients still develop this complication and suﬀ  er from its 
consequences. Th  erefore, new drugs are under investi-
gation, to be used as adjunct therapy. Magnesium sulfate 
is a promising drug that is presently being investigated in 
randomized trials.
In the current study, Wong and colleagues performed a 
systematic review and meta-analysis update of random-
ized controlled trials that investigated the eﬃ   cacy  of 
magnesium sulfate in patients with aneurysmal SAH [1]. 
Th  e present meta-analysis diﬀ  ers from previous meta-
analyses in that it included the results of two recently 
published randomized trials [2,3]. Six trials were re-
trieved including 875 patients. Outcome measures were 
DCI, cerebral infarction, and functional outcome 3 and 
6  months after SAH. Th  e number of patients for the 
various meta-analyses ranged between 381 and 494. Th  e 
results showed that magnesium sulfate decreased the rate 
of cerebral infarction, but not of DCI or poor functional 
outcome.
Recently, it has been proposed that the main outcome 
measures of clinical trials and observational studies that 
investigate the complication of DCI should be cerebral 
infarction and functional outcome [4]. Arterial narrowing 
(vasospasm) is a radiographic ﬁ   nding associated with 
clinical deterioration due to DCI, cerebral infarction, and 
functional outcome. However, it is still under debate if 
these associations represent causal relationships. Vaso-
spasm is often asymptomatic, and a reduction of vaso-
spasm does not result in better functional outcomes [5]. 
Clinical deterioration due to DCI is less reliable than 
cerebral infarction, since it is more likely subject to inter-
observer bias. Cerebral infarction represents the ultimate 
outcome of the ischemic event, while clinical deteriora-
tion due to DCI is a diagnosis per exclusionem. Clinical 
deterioration after SAH can have multiple causes, such as 
infections, seizures, electrolyte disturbances, and hydro-
cephalus. Th   e present meta-analysis used both DCI and 
cerebral infarction as outcome measures, and only found 
a beneﬁ  cial eﬀ  ect on cerebral infarction. Th  is eﬀ  ect on 
cerebral infarction did not translate to a beneﬁ  cial eﬀ  ect 
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on outcome can not be ruled out because of the relatively 
low number of included patients.
Even if the present meta-analysis had shown a bene-
ﬁ  cial eﬀ  ect of magnesium sulfate on functional outcome, 
an important unanswered question would be which 
treatment protocol should be applied in daily practice. 
Th   e administration of magnesium sulfate diﬀ  ered between 
most included studies. Th   e concentration of magnesium 
sulfate was either 64 or 80 mmol/day, with or without 
initial bolus, and with or without dosage adjustment 
according to serum magnesium levels. Th   e Magnesium in 
Aneurysmal Subarachnoid Hemorrhage-II (MASH-II: 
ISRCTN68742385) phase III clinical trial will hopefully 
shed more light on the eﬃ   cacy of magnesium sulfate in 
this group of patients. MASH-II aims to include 1,200 
patients, which is based on a relative risk reduction of 
poor functional outcome of 22% (with alpha = 5% and a 
power of 80%) [6]. In MASH-II, magnesium sulfate 
64  mmol/day or placebo is started within 4 days after 
SAH and continued until 20 days after the hemorrhage. 
Th  is trial nears completion and its results are to be 
expected soon.
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